Alcon presented data on SYSTANE PRO PF at Academy 2026
Alcon announced its participation in Academy 2026 in Anaheim (Sep 30 – Oct 3) and on Oct 1 presented study results showing SYSTANE PRO PF was non‑inferior to MIEBO in relieving dry‑eye symptoms.
Key points
- Alcon said it will take part in Academy 2026 in Anaheim and on Oct 1 released study results in which SYSTANE PRO PF was non‑inferior to MIEBO in easing dry‑eye symptoms.
- The study involves patients with dry eye who can use SYSTANE PRO PF.
- In a prospective, randomized study, SYSTANE PRO PF showed non‑inferiority to MIEBO in relieving dry eye, achieving the primary endpoint of non‑inferiority on the OSDI scale at two weeks and one month.
What happened
Alcon said it will take part in Academy 2026 in Anaheim and on Oct 1 released study results in which SYSTANE PRO PF was non‑inferior to MIEBO in easing dry‑eye symptoms.
Who is affected
The study involves patients with dry eye who can use SYSTANE PRO PF.
Evidence
In a prospective, randomized study, SYSTANE PRO PF showed non‑inferiority to MIEBO in relieving dry eye, achieving the primary endpoint of non‑inferiority on the OSDI scale at two weeks and one month.
Next steps
Alcon gave no details on further regulatory or commercial actions; assessing the results’ impact will require additional data on physician uptake and formulary inclusion.
Original sources
- Alcon to Showcase Extensive Scientific Research, Immersive Experiences and Innovation at Academy 2026
- SYSTANE PRO Preservative-Free Demonstrates Clinically Comparable Dry Eye Symptom Relief to MIEBO (perfluorohexyloctane ophthalmic solution) in a Prospective, Randomized Clinical Study
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Alcon
A notification in your browser or on your phone when we publish about Alcon. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
